TCM Biotech International Corp. (TPEX: 4169)
Taiwan
· Delayed Price · Currency is TWD 59.60
-0.40 (-0.67%)
Sep 10, 2024, 2:49 PM CST
TCM Biotech International Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Revenue | 834.32 | 969.62 | 802.42 | 702.05 | 737.08 | 568.63 | Upgrade
|
| Revenue Growth (YoY) | -6.75% | 20.84% | 14.30% | -4.75% | 29.62% | 5.26% | Upgrade
|
| Cost of Revenue | 422.87 | 489.45 | 353.93 | 343.33 | 368.15 | 295.33 | Upgrade
|
| Gross Profit | 411.45 | 480.17 | 448.49 | 358.72 | 368.92 | 273.3 | Upgrade
|
| Selling, General & Admin | 302.49 | 380.38 | 340.9 | 276.14 | 259.59 | 215.14 | Upgrade
|
| Research & Development | 83.25 | 77.46 | 81.8 | 80.45 | 71.53 | 44.63 | Upgrade
|
| Operating Expenses | 385.06 | 457.84 | 423.19 | 356.59 | 331.87 | 259.59 | Upgrade
|
| Operating Income | 26.4 | 22.33 | 25.3 | 2.13 | 37.05 | 13.71 | Upgrade
|
| Interest Expense | -2.27 | -2.77 | -2.39 | -1.97 | -1.95 | -2.2 | Upgrade
|
| Interest & Investment Income | 3.56 | 1.55 | 0.14 | 0.04 | 0.07 | 0.1 | Upgrade
|
| Currency Exchange Gain (Loss) | -0.12 | -0.12 | 0.01 | 0.44 | -0.55 | 0.05 | Upgrade
|
| Other Non Operating Income (Expenses) | -3.88 | 1.05 | 0.07 | 0.71 | 0.16 | 1.08 | Upgrade
|
| EBT Excluding Unusual Items | 23.68 | 22.03 | 23.13 | 1.35 | 34.78 | 12.74 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | - | - | 0.91 | 1.35 | 0.21 | Upgrade
|
| Other Unusual Items | - | - | - | - | - | -0.02 | Upgrade
|
| Pretax Income | 23.68 | 22.03 | 23.13 | 2.26 | 36.13 | 12.93 | Upgrade
|
| Income Tax Expense | 3.68 | 3.46 | 4.86 | 0.38 | 10.59 | 6.41 | Upgrade
|
| Net Income | 20 | 18.57 | 18.27 | 1.87 | 25.54 | 6.51 | Upgrade
|
| Net Income to Common | 20 | 18.57 | 18.27 | 1.87 | 25.54 | 6.51 | Upgrade
|
| Net Income Growth | 49.02% | 1.69% | 875.17% | -92.67% | 292.17% | -73.74% | Upgrade
|
| Shares Outstanding (Basic) | 58 | 53 | 49 | 49 | 48 | 48 | Upgrade
|
| Shares Outstanding (Diluted) | 58 | 53 | 49 | 49 | 48 | 48 | Upgrade
|
| Shares Change (YoY) | 18.23% | 8.03% | 0.89% | 0.42% | -0.03% | -1.33% | Upgrade
|
| EPS (Basic) | 0.34 | 0.35 | 0.37 | 0.04 | 0.53 | 0.13 | Upgrade
|
| EPS (Diluted) | 0.34 | 0.35 | 0.37 | 0.04 | 0.52 | 0.13 | Upgrade
|
| EPS Growth | 26.25% | -5.41% | 861.49% | -92.66% | 289.83% | -73.36% | Upgrade
|
| Free Cash Flow | 47.47 | -41.51 | 48.46 | 11.19 | 71.96 | -23.17 | Upgrade
|
| Free Cash Flow Per Share | 0.82 | -0.78 | 0.99 | 0.23 | 1.48 | -0.48 | Upgrade
|
| Dividend Per Share | 0.285 | 0.285 | 0.033 | - | 0.349 | 0.388 | Upgrade
|
| Dividend Growth | 763.64% | 763.64% | - | - | -10.00% | 5.26% | Upgrade
|
| Gross Margin | 49.32% | 49.52% | 55.89% | 51.10% | 50.05% | 48.06% | Upgrade
|
| Operating Margin | 3.16% | 2.30% | 3.15% | 0.30% | 5.03% | 2.41% | Upgrade
|
| Profit Margin | 2.40% | 1.92% | 2.28% | 0.27% | 3.47% | 1.15% | Upgrade
|
| Free Cash Flow Margin | 5.69% | -4.28% | 6.04% | 1.59% | 9.76% | -4.07% | Upgrade
|
| EBITDA | 43.83 | 39.52 | 40.86 | 16.42 | 50.35 | 28.13 | Upgrade
|
| EBITDA Margin | 5.25% | 4.08% | 5.09% | 2.34% | 6.83% | 4.95% | Upgrade
|
| D&A For EBITDA | 17.43 | 17.19 | 15.56 | 14.29 | 13.3 | 14.43 | Upgrade
|
| EBIT | 26.4 | 22.33 | 25.3 | 2.13 | 37.05 | 13.71 | Upgrade
|
| EBIT Margin | 3.16% | 2.30% | 3.15% | 0.30% | 5.03% | 2.41% | Upgrade
|
| Effective Tax Rate | 15.52% | 15.70% | 21.02% | 17.01% | 29.31% | 49.62% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.